Oncotherm has been developing, manufacturing and marketing cancer treatment systems since 1988 applying the patented oncothermia technology to treat malignant tumors. The technology of oncothermia - modulated-electro-hyperthermia, mEHT® - is a modern enhancement of one of the oldest cancer treatment methods, classical hyperthermia. Oncothermia is a personalized, non-toxic therapy that uses an electric field to selectively eliminate cancer cells and promote the body's natural regulatory processes.
GBM treatment results
How does mEHT® work?
A capacitive arrangement of two electrodes and the amplifier generate a modulated electromagnetic field with a carrier frequency of 13.56 MHz. Since malignant tissue has higher conductivity than the healthy host’s tissue, the electric field tends to concentrate predominantly in the malignant lesion. The combination of the deep heating - by the radiofrequency passing through the body, and with the focused electric field, - could stimulate the immune system, trigger tumorspecific immune reactions all over the body, and cause the programmed cell-death (apoptosis) of the selected malignant-cells.
Clinical trials
Phase III Randomised controlled cervix trial (n=210) - 5-year disease free survival*
Oncotherm has established a cooperation with Marqués de Valdecilla University Hospital in Spain and with several institutes of Semmelweis University in Hungary to conduct a clinical trial using EHY-2030. It also has a partnership with Charité – Universitätsmedizin Berlin in Germany and University College London Hospital in the United Kingdom where the clinical trials are ready to begin.
EHY-2030
Loco-regional modulated electro-hyperthermia (mEHT) device
The EHY-2030 represents a significant advancement in hyperthermia treatment, offering enhanced capabilities for the targeted treatment of loco-regional tumors. This innovative technology integrates seamlessly into combination regimens with chemotherapy and radiation therapy, providing a complementary approach to improving patient outcomes. Oncotherm’s ISO:13485 TÜV (Germany) certification and the obtained CE mark of the EHY-2030 device underscore the company’s dedication to maintaining high-quality standards in medical device development.
Oncothermia Clinics
600devices |
+ |
35countries |
+ |
450 000treatment per year |
+ |